- Home
- RYAN vs BPMC Comparison
RYAN vs BPMC Comparison
Compare RYAN & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYAN
- BPMC
- Stock Information
- Founded
- RYAN 2010
- BPMC 2008
- Country
- RYAN United States
- BPMC United States
- Employees
- RYAN N/A
- BPMC N/A
- Industry
- RYAN Specialty Insurers
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- RYAN Finance
- BPMC Health Care
- Exchange
- RYAN Nasdaq
- BPMC Nasdaq
- Market Cap
- RYAN 8.8B
- BPMC 8.3B
- IPO Year
- RYAN 2021
- BPMC 2015
- Fundamental
- Price
- RYAN $65.76
- BPMC $129.46
- Analyst Decision
- RYAN Buy
- BPMC Buy
- Analyst Count
- RYAN 13
- BPMC 18
- Target Price
- RYAN $73.55
- BPMC $128.87
- AVG Volume (30 Days)
- RYAN 988.9K
- BPMC 4.3M
- Earning Date
- RYAN 07-31-2025
- BPMC 07-31-2025
- Dividend Yield
- RYAN 0.73%
- BPMC N/A
- EPS Growth
- RYAN N/A
- BPMC N/A
- EPS
- RYAN 0.27
- BPMC N/A
- Revenue
- RYAN $2,593,912,000.00
- BPMC $562,121,000.00
- Revenue This Year
- RYAN $27.79
- BPMC $44.46
- Revenue Next Year
- RYAN $15.39
- BPMC $32.78
- P/E Ratio
- RYAN $242.88
- BPMC N/A
- Revenue Growth
- RYAN 22.53
- BPMC 99.19
- 52 Week Low
- RYAN $56.59
- BPMC $73.04
- 52 Week High
- RYAN $77.16
- BPMC $129.65
- Technical
- Relative Strength Index (RSI)
- RYAN 44.55
- BPMC 3.63
- Support Level
- RYAN $63.53
- BPMC $129.20
- Resistance Level
- RYAN $67.70
- BPMC $129.65
- Average True Range (ATR)
- RYAN 1.50
- BPMC 0.24
- MACD
- RYAN 0.04
- BPMC -9.00
- Stochastic Oscillator
- RYAN 43.46
- BPMC 0.00
About RYAN Ryan Specialty Holdings Inc.
Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.